Table 3

Arz and LG268 synergize in treatment of early invasive breast cancer in rats

TreatmentaNo. of tumor-free rats/total no. of rats (P1; P2)bAverage no. of tumors (P1; P2)ATBc (P1; P2)Rats with 3 or more tumors (P1; P2)Rats with tumor burden > 5 g (P1; P2)
Control (vehicle)0/455.014.941/4542/45
Arz (60)d0/222.8 (0.002)3.7 (0.0002)9/22 (<0.0001)7/22 (<0.0001)
Arz (20)1/223.7 (0.009)5.3 (0.001)16/22 (0.06)10/22 (<0.0001)
LG268 (200)2/221.8 (0.0002)1.0 (<0.0001)5/22 (<0.0001)1/22 (<0.0001)
LG268 (60)0/223.1 (0.0004)5.5 (0.001)14/22 (0.01)11/22 (0.0001)
Arz (60) + LG268 (200)2/22 (0.1; 0.5)2.0 (0.0002; 0.05)0.3 (<0.0001; <0.0001)7/22 (<0.0001; 0.8)0/22 (<0.0001; 0.009)
Arz (60) + LG268 (60)3/22 (0.04; 0.2)1.5 (<0.0001; 0.008)0.5 (<0.0001; 0.0002)3/22 (<0.0001; 0.09)0/22 (<0.0001; 0.009)
Arz (20) + LG268 (200)3/22 (0.04; 0.6)1.7 (<0.0001; 0.001)0.4 (<0.0001; 0.0001)5/22 (<0.0001; 0.002)0/22 (<0.0001; 0.0005)
Arz (20) + LG268 (60)3/22 (0.04; 0.6)2.0 (0.0003; 0.008)1.1 (<0.0001; 0.0004)10/22 (<0.0001; 0.1)2/22 (<0.0001; 0.02)
  • a All rats received NMU (50 mg/kg, i.p.) when they were 21 days old. All tumors were measured weekly by calipers. When tumors were > 10 × 10 mm, rats were randomly assigned to treatment groups and fed chemopreventive agents for 3 weeks before autopsy. “Tumor-free” in column 2 refers to the grossly detectable status of rats at the end of the experiment; all rats had a tumor at the beginning.

  • b P1 is the value for the comparison of rats treated with chemopreventive agents with control rats treated with vehicle alone; P2 is the value for the comparison of rats treated with Arz + LG268 with rats treated with Arz alone.

  • c ATB, average tumor burden (average weight in grams of a rat’s tumor at autopsy).

  • d All doses are shown as mg/kg diet.